Country: মার্কিন যুক্তরাষ্ট্র
ভাষা: ইংরেজি
সূত্র: NLM (National Library of Medicine)
RABEPRAZOLE SODIUM (UNII: 3L36P16U4R) (RABEPRAZOLE - UNII:32828355LL)
Breckenridge Pharmaceutical, Inc.
RABEPRAZOLE SODIUM
RABEPRAZOLE SODIUM 20 mg
ORAL
PRESCRIPTION DRUG
Rabeprazole Sodium Delayed-Release Tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Rabeprazole Sodium Delayed-Release Tablets may be considered. Rabeprazole Sodium Delayed-Release Tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. Rabeprazole Sodium Delayed-Release Tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks. Rabeprazole Sodium Delayed-Release Tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. Rabeprazole
Rabeprazole Sodium Delayed-Release Tablets 20 mg are supplied as light yellow colored round, biconvex tablets with beveled edges and B683 printed on one side with black ink and plain on the other side. Bottles of 30 (NDC#51991-683-33) Bottles of 90 (NDC#51991-683-90) Bottles of 500 (NDC#51991-683-05) Bottles of 1,000 (NDC#51991-683-10) Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [ see USP Controlled Room Temperature] . Protect from moisture.
Abbreviated New Drug Application
Breckenridge Pharmaceutical, Inc. ---------- MEDICATION GUIDE Rabeprazole Sodium (ra-bep-ra-zole soe-dee-um) Delayed-Release Tablets Read the Medication Guide that comes with Rabeprazole Sodium Delayed-Release Tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. What is the most important information I should know about Rabeprazole Sodium Delayed-Release Tablets? Rabeprazole Sodium Delayed-Release Tablets may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor. Rabeprazole Sodium Delayed-Release Tablets can cause serious side effects, including: • A type of kidney problem (acute interstitial nephritis). Some people who take proton pump inhibitor (PPI) medicines, including Rabeprazole Sodium Delayed-Release Tablets, may develop a kidney problem called acute interstitial nephritis that can happen at any time during treatment with Rabeprazole Sodium Delayed-Release Tablets. Call your doctor if you have a decrease in the amount that you urinate or if you have blood in your urine. • Diarrhea. Rabeprazole Sodium Delayed-Release Tablets may increase your risk of getting severe diarrhea. This diarrhea may be caused by an infection (Clostridium difficile) in your intestines. Call your doctor right away if you have watery stool, stomach pain, and fever that does not go away. • Bone fractures. People who take multiple daily doses of PPI medicines for a long period of time (1 year or longer) may have an increased risk of fractures of the hip, wrist, or spine. You should take Rabeprazole Sodium Delayed-Release Tablets exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. • Certain types of lupus erythematosus. Lupus erythematosus is an autoimmune disorder (the body's immune cells attack other cells or organs in the body). Some people who take PPI medicines, in সম্পূর্ণ নথি পড়ুন
RABEPRAZOLE SODIUM- RABEPRAZOLE SODIUM TABLET, DELAYED RELEASE BRECKENRIDGE PHARMACEUTICAL, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RABEPRAZOLE SODIUM DELAYED- RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS. RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1999 RECENT MAJOR CHANGES Contraindications (4) 04/2016 Warnings and Precautions, Cutaneous and Systemic Lupus Erythematosus (5.6) 10/2016 INDICATIONS AND USAGE Rabeprazole Sodium Delayed-Release Tablets are a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) (1.1). Maintenance of Healing of Erosive or Ulcerative GERD (1.2). Treatment of Symptomatic GERD (1.3). Healing of Duodenal Ulcers (1.4). _Helicobacter pylori_ Eradication to Reduce the Risk of Duodenal Ulcer Recurrence (1.5). Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome (1.6). In adolescent patients 12 years of age and older for: Short-term treatment of Symptomatic GERD (1.7). DOSAGE AND ADMINISTRATION INDIC ATIO N RECOMMENDED DOSAGE (2) * Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily for 4 to 8 weeks Maintenance of Healing of Erosive or Ulcerative GERD 20 mg once daily Symptomatic GERD in Adults 20 mg once daily for 4 weeks Healing of Duodenal Ulcers 20 mg once daily after morning meal for up to 4 weeks _Helicobacter pylori_ Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Three Drug Regimen: Rabeprazole Sodium Delayed-Release Tablets 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg _All three medications should be taken twice daily with_ _morning and evening meals for 7 days_ Pathological Hypersecretory Conditions, Including Zollinger- Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs Symptomatic GERD in Adolescents 12 Years o সম্পূর্ণ নথি পড়ুন